Latest Videos

Paul Collinson, St Georges Healthcare NHS Trust, speaking at Point of Care Diagnostics 2015

This presentation will outline key issues in oncology biomarker testing and describe findings from a study of practices used by National Cancer Institute (NCI) designated cancer centers, the leading U.S. oncology institutions, for testing key biomarkers in three solid tumors - breast, gastroesophageal and non-small cell lung cancers.

The chip-system is capable of extracting miRNAs from tumor cell cultures, fresh frozen cells and archive material samples by on-chip gel electrophoresis.

A lab-on-a-chip system called the "Fraunhofer ivD-platform" has been established which opens up the possibility for an on-site analysis at low costs.

Centrifugal microfluidics enables efficient miniaturization, integration, parallelization and automation of biochemical assays especially for Point-of-Care applications.

Richard Luxton, University of the West of England, speaking at Point of Care Diagnostics 2015

Imaging has been at the heart of Medicine for many decades. However, its influence is changing as the need increases not only for diagnosis of disease, but also for quantification of disease extent, identification of suitable candidates for treatment and for testing of both treatment response or assessment of potential side effects for new treatments.

Present diagnostic procedures and therapeutic strategies solid tumours rely on the detection and targeting of specific marker molecules to classify the tumour and to design an efficient therapy.

Seth Crosby, Washington University School of Medicine, discusses both bench and informatic methods used to increase specificity in the apprehension of rare cfDNA alleles.

Jeff Cummings presents a worked example of circulating tumour cell enumeration as a prognostic/predictive biomarker in cancer research.